Soluble and Membrane-Bound TGF-β-Mediated Regulation of Intratumoral T Cell Differentiation and Function in B-Cell Non-Hodgkin Lymphoma

PLoS ONE

Volumn 8, Issue 3, 2013, Pages

  Yang, Zhi Zhang ^a   Grote, Deanna M ^a   Ziesmer, Steven C ^a   Xiu, Bing ^b   Yates, Nicole R ^a   Secreto, Frank J ^a   Hodge, Lucy S ^a   Witzig, Thomas E ^a   Novak, Anne J ^a   Ansell, Stephen M ^a  

^a Mayo Clinic College of Medicine   (United States)

^b TONGJI UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

GAMMA INTERFERON; INTERLEUKIN 17; TRANSCRIPTION FACTOR FOXP3; TRANSFORMING GROWTH FACTOR BETA;

ARTICLE; B CELL LYMPHOMA; CD4+ T LYMPHOCYTE; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOKINE RELEASE; HELPER CELL; HUMAN; HUMAN CELL; HUMAN TISSUE; LYMPHOCYTE DIFFERENTIATION; LYMPHOCYTE FUNCTION; LYMPHOCYTE PROLIFERATION; PROTEIN BINDING; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; PROTEIN SYNTHESIS INHIBITION; REGULATORY T LYMPHOCYTE; SIGNAL TRANSDUCTION; TUMOR MICROENVIRONMENT;

B-LYMPHOCYTES; CELL DIFFERENTIATION; CELL LINE, TUMOR; CELL MEMBRANE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; INTERLEUKIN-2; LYMPHOMA, NON-HODGKIN; SIGNAL TRANSDUCTION; SOLUBILITY; T-LYMPHOCYTES; TRANSFORMING GROWTH FACTOR BETA; TUMOR MICROENVIRONMENT;

EID: 84875035674     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0059456     Document Type: Article

References (48)

1. Li MO, Wan YY, Sanjabi S, Robertson AK, Flavell RA, (2006) Transforming growth factor-beta regulation of immune responses. Annual review of immunology 24: 99-146.
2. Harrington LE, Hatton RD, Mangan PR, Turner H, Murphy TL, et al. (2005) Interleukin 17-producing CD4+ effector T cells develop via a lineage distinct from the T helper type 1 and 2 lineages. Nat Immunol 6: 1123-1132.
3. Bettelli E, Carrier Y, Gao W, Korn T, Strom TB, et al. (2006) Reciprocal developmental pathways for the generation of pathogenic effector TH17 and regulatory T cells. Nature 441: 235-238.
4. Flavell RA, Sanjabi S, Wrzesinski SH, Licona-Limon P, (2010) The polarization of immune cells in the tumour environment by TGFbeta. Nature reviews Immunology 10: 554-567.
5. Nakamura K, Kitani A, Strober W, (2001) Cell contact-dependent immunosuppression by CD4(+)CD25(+) regulatory T cells is mediated by cell surface-bound transforming growth factor beta. J Exp Med 194: 629-644.
6. Oida T, Zhang X, Goto M, Hachimura S, Totsuka M, et al. (2003) CD4+CD25- T cells that express latency-associated peptide on the surface suppress CD4+CD45RBhigh-induced colitis by a TGF-beta-dependent mechanism. J Immunol 170: 2516-2522.
7. Ghiringhelli F, Menard C, Terme M, Flament C, Taieb J, et al. (2005) CD4+CD25+ regulatory T cells inhibit natural killer cell functions in a transforming growth factor-beta-dependent manner. J Exp Med 202: 1075-1085.
8. Ostroukhova M, Seguin-Devaux C, Oriss TB, Dixon-McCarthy B, Yang L, et al. (2004) Tolerance induced by inhaled antigen involves CD4(+) T cells expressing membrane-bound TGF-beta and FOXP3. The Journal of clinical investigation 114: 28-38.
9. Han Y, Guo Q, Zhang M, Chen Z, Cao X, (2009) CD69+ CD4+ CD25- T cells, a new subset of regulatory T cells, suppress T cell proliferation through membrane-bound TGF-beta 1. Journal of immunology 182: 111-120.
10. Vega JL, Saban D, Carrier Y, Masli S, Weiner HL, (2010) Retinal pigment epithelial cells induce foxp3(+) regulatory T cells via membrane-bound TGF-beta. Ocular immunology and inflammation 18: 459-469.
11. Yamada Y, Sugita S, Horie S, Yamagami S, Mochizuki M, (2010) Mechanisms of immune suppression for CD8+ T cells by human corneal endothelial cells via membrane-bound TGFbeta. Investigative ophthalmology & visual science 51: 2548-2557.
12. Xie Y, Bai O, Yuan J, Chibbar R, Slattery K, et al. (2009) Tumor apoptotic bodies inhibit CTL responses and antitumor immunity via membrane-bound transforming growth factor-beta1 inducing CD8+ T-cell anergy and CD4+ Tr1 cell responses. Cancer research 69: 7756-7766.
13. Ahn YO, Lee JC, Sung MW, Heo DS, (2009) Presence of membrane-bound TGF-beta1 and its regulation by IL-2-activated immune cell-derived IFN-gamma in head and neck squamous cell carcinoma cell lines. Journal of immunology 182: 6114-6120.
14. Baker K, Raut P, Jass JR, (2008) Colorectal cancer cells express functional cell surface-bound TGFbeta. International journal of cancer Journal international du cancer 122: 1695-1700.
15. Isufi I, Seetharam M, Zhou L, Sohal D, Opalinska J, et al. (2007) Transforming growth factor-beta signaling in normal and malignant hematopoiesis. Journal of interferon & cytokine research: the official journal of the International Society for Interferon and Cytokine Research 27: 543-552.
16. Bollard CM, Rossig C, Calonge MJ, Huls MH, Wagner HJ, et al. (2002) Adapting a transforming growth factor beta-related tumor protection strategy to enhance antitumor immunity. Blood 99: 3179-3187.
17. Foster AE, Dotti G, Lu A, Khalil M, Brenner MK, et al. (2008) Antitumor activity of EBV-specific T lymphocytes transduced with a dominant negative TGF-beta receptor. J Immunother 31: 500-505.
18. Chung JS, Shiue LH, Duvic M, Pandya A, Cruz PD Jr, et al. (2011) Sezary syndrome cells overexpress syndecan-4 bearing distinct heparan sulfate moieties that suppress T-cell activation by binding DC-HIL and trapping TGF-beta on the cell surface. Blood 117: 3382-3390.
19. Yang ZZ, Novak AJ, Stenson MJ, Witzig TE, Ansell SM, (2006) Intratumoral CD4+CD25+ regulatory T-cell-mediated suppression of infiltrating CD4+ T cells in B-cell non-Hodgkin lymphoma. Blood 107: 3639-3646.
20. Yang ZZ, Novak AJ, Ziesmer SC, Witzig TE, Ansell SM, (2006) Attenuation of CD8(+) T-cell function by CD4(+)CD25(+) regulatory T cells in B-cell non-Hodgkin's lymphoma. Cancer Res 66: 10145-10152.
21. Yang ZZ, Novak AJ, Ziesmer SC, Witzig TE, Ansell SM, (2009) Malignant B cells skew the balance of regulatory T cells and TH17 cells in B-cell non-Hodgkin's lymphoma. Cancer Res 69: 5522-5530.
22. Yang ZZ, Novak AJ, Ziesmer SC, Witzig TE, Ansell SM, (2007) CD70+ non-Hodgkin lymphoma B cells induce Foxp3 expression and regulatory function in intratumoral CD4+CD25 T cells. Blood 110: 2537-2544.
23. Tweeddale ME, Lim B, Jamal N, Robinson J, Zalcberg J, et al. (1987) The presence of clonogenic cells in high-grade malignant lymphoma: a prognostic factor. Blood 69: 1307-1314.
24. Chang H, Blondal JA, Benchimol S, Minden MD, Messner HA, (1995) p53 mutations, c-myc and bcl-2 rearrangements in human non-Hodgkin's lymphoma cell lines. Leuk Lymphoma 19: 165-171.
25. Ditzel Santos D, Ho AW, Tournilhac O, Hatjiharissi E, Leleu X, et al. (2007) Establishment of BCWM.1 cell line for Waldenstrom's macroglobulinemia with productive in vivo engraftment in SCID-hu mice. Exp Hematol 35: 1366-1375.
26. Hodge LS, Novak AJ, Grote DM, Braggio E, Ketterling RP, et al. (2011) Establishment and characterization of a novel Waldenstrom macroglobulinemia cell line, MWCL-1. Blood 117: e190-197.
27. Fischer P, Nacheva E, Mason DY, Sherrington PD, Hoyle C, et al. (1988) A Ki-1 (CD30)-positive human cell line (Karpas 299) established from a high-grade non-Hodgkin's lymphoma, showing a 2;5 translocation and rearrangement of the T-cell receptor beta-chain gene. Blood 72: 234-240.
28. del Mistro A, Leszl A, Bertorelle R, Calabro ML, Panozzo M, et al. (1994) A CD30-positive T cell line established from an aggressive anaplastic large cell lymphoma, originally diagnosed as Hodgkin's disease. Leukemia 8: 1214-1219.
29. Yang ZZ, Grote DM, Ziesmer SC, Manske MK, Witzig TE, et al. (2011) Soluble IL-2Ralpha facilitates IL-2-mediated immune responses and predicts reduced survival in follicular B-cell non-Hodgkin lymphoma. Blood 118: 2809-2820.
30. Levy L, Hill CS, (2006) Alterations in components of the TGF-beta superfamily signaling pathways in human cancer. Cytokine & growth factor reviews 17: 41-58.
31. McCaffrey TA, Falcone DJ, Du B, (1992) Transforming growth factor-beta 1 is a heparin-binding protein: identification of putative heparin-binding regions and isolation of heparins with varying affinity for TGF-beta 1. Journal of cellular physiology 152: 430-440.
32. Lyon M, Rushton G, Gallagher JT, (1997) The interaction of the transforming growth factor-betas with heparin/heparan sulfate is isoform-specific. The Journal of biological chemistry 272: 18000-18006.
33. Couchman JR, (2010) Transmembrane signaling proteoglycans. Annual review of cell and developmental biology 26: 89-114.
34. Wilson NJ, Boniface K, Chan JR, McKenzie BS, Blumenschein WM, et al. (2007) Development, cytokine profile and function of human interleukin 17-producing helper T cells. Nature immunology 8: 950-957.
35. Ahmadzadeh M, Rosenberg SA, (2006) IL-2 administration increases CD4+ CD25(hi) Foxp3+ regulatory T cells in cancer patients. Blood 107: 2409-2414.
36. Zorn E, Nelson EA, Mohseni M, Porcheray F, Kim H, et al. (2006) IL-2 regulates FOXP3 expression in human CD4+CD25+ regulatory T cells through a STAT-dependent mechanism and induces the expansion of these cells in vivo. Blood 108: 1571-1579.
37. Laurence A, Tato CM, Davidson TS, Kanno Y, Chen Z, et al. (2007) Interleukin-2 signaling via STAT5 constrains T helper 17 cell generation. Immunity 26: 371-381.
38. Das L, Levine AD, (2008) TGF-beta inhibits IL-2 production and promotes cell cycle arrest in TCR-activated effector/memory T cells in the presence of sustained TCR signal transduction. Journal of immunology 180: 1490-1498.
39. Bright JJ, Kerr LD, Sriram S, (1997) TGF-beta inhibits IL-2-induced tyrosine phosphorylation and activation of Jak-1 and Stat 5 in T lymphocytes. Journal of immunology 159: 175-183.
40. Han SH, Yea SS, Jeon YJ, Yang KH, Kaminski NE, (1998) Transforming growth factor-beta 1 (TGF-beta1) promotes IL-2 mRNA expression through the up-regulation of NF-kappaB, AP-1 and NF-AT in EL4 cells. The Journal of pharmacology and experimental therapeutics 287: 1105-1112.
41. McKarns SC, Kaminski NE, (2000) TGF-beta 1 differentially regulates IL-2 expression and [3H]-thymidine incorporation in CD3 epsilon mAb- and CD28 mAb-activated splenocytes and thymocytes. Immunopharmacology 48: 101-115.
42. Chen G, Ghosh P, Osawa H, Sasaki CY, Rezanka L, et al. (2007) Resistance to TGF-beta 1 correlates with aberrant expression of TGF-beta receptor II in human B-cell lymphoma cell lines. Blood 109: 5301-5307.
43. Inman GJ, Allday MJ, (2000) Resistance to TGF-beta1 correlates with a reduction of TGF-beta type II receptor expression in Burkitt's lymphoma and Epstein-Barr virus-transformed B lymphoblastoid cell lines. J Gen Virol 81: 1567-1578.
44. Sing GK, Ruscetti FW, Beckwith M, Keller JR, Ellingsworth L, et al. (1990) Growth inhibition of a human lymphoma cell line: induction of a transforming growth factor-beta-mediated autocrine negative loop by phorbol myristate acetate. Cell Growth Differ 1: 549-557.
45. Macri L, Silverstein D, Clark RA, (2007) Growth factor binding to the pericellular matrix and its importance in tissue engineering. Adv Drug Deliv Rev 59: 1366-1381.
46. Butzow R, Fukushima D, Twardzik DR, Ruoslahti E, (1993) A 60-kD protein mediates the binding of transforming growth factor-beta to cell surface and extracellular matrix proteoglycans. J Cell Biol 122: 721-727.
47. Piek E, Franzen P, Heldin CH, ten Dijke P, (1997) Characterization of a 60-kDa cell surface-associated transforming growth factor-beta binding protein that can interfere with transforming growth factor-beta receptor binding. Journal of cellular physiology 173: 447-459.
48. McCaffrey TA, Falcone DJ, Vicente D, Du B, Consigli S, et al. (1994) Protection of transforming growth factor-beta 1 activity by heparin and fucoidan. J Cell Physiol 159: 51-59.